Interesting, the two patients (one in each dose level group) with disease progression in our ongoing P1 CHM1101 trial also happen to be the ones that received the least number of doses, while the other five patients with more than 3 doses received achieved disease control for glioblastoma:
Chimeric: Media Thread, page-445
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| CHM (ASX) Chart |
Day chart unavailable